Special Issue

Glomerular Microenvironment: Cellular Stress in Chronic Kidney Disease 2.0

Message from the Guest Editor

Chronic kidney disease (CKD) is a global public health problem affecting people from all segments of society. The renal glomerulus (in particular, the filtration barrier) is the main target of these disorders. Its structure constitutes a special and unique microenvironment whose integrity is maintained by the molecular interaction between three central components: the endothelial cell, the basement membrane and the podocytes. This architecture must be finely preserved because its destabilization, through extraordinarily complex molecular mechanisms, can lead to the onset of severe proteinuria. This structural complexity limits the availability of reliable experimental models. Recent advances in regenerative medicine, organoids, as well as the design of microfluidic platforms or other devices, constitute promising models for the study of CKD. This Special Issue is a continuation of a previous issue on this topic. It will serve as a report on the state of basic and translational research in the field of nephrotic syndrome pathogenesis: molecular mechanisms and new experimental models.

Guest Editor

Dr. Hans-Kristian Lorenzo

1. Faculté de Médecine, Université Paris-Saclay, 94270 Le Kremlin-Bicêtre, France
2. Bicêtre Hospital, Department of Nephrology, 94270 Le Kremlin-Bicêtre, France
3. INSERM U1197, 14 Avenue Paul Vaillant Couturier, 94807 Villejuif, France

Deadline for manuscript submissions

closed (31 December 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/140764

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).